Today's digest: Vertex advances toward FDA filing for its kidney disease drug povetacicept after positive phase 3 data, while UCB's Bimzelx defeated AbbVie's Skyrizi in a head-to-head psoriatic arthritis trial. On the manufacturing front, Lilly committed $3B to China operations for oral GLP-1 production, and BioNTech's co-founders stepped down to launch a new mRNA venture.
Top Stories
Vertex preps FDA filing for IgAN drug povetacicept after phase 3 win
Vertex Pharmaceuticals is preparing an FDA submission for povetacicept following positive phase 3 results in IgA nephropathy, a severe kidney disorder, according to pharmaphorum. The data represents a significant milestone in Vertex's diversification strategy beyond cystic fibrosis treatments. This signals Vertex's broader ambitions to build a multi-franchise portfolio in rare and serious diseases.
UCB's Bimzelx outperforms AbbVie's Skyrizi in psoriatic arthritis head-to-head
UCB's Bimzelx has notched another competitive victory, this time defeating AbbVie's blockbuster Skyrizi in a phase 3b head-to-head trial for psoriatic arthritis, Fierce Pharma reported. This follows three prior wins against established psoriasis treatments in comparative studies. The continued success in comparative effectiveness trials positions Bimzelx as a formidable commercial challenger in the crowded immunology market.
FDA approves GSK's leucovorin for ultra-rare cerebral folate deficiency, not autism
The FDA has cleared a repurposed GSK drug, leucovorin (Wellcovorin), for cerebral folate deficiency—a condition documented in fewer than 50 people—rather than for autism as some had hoped, according to BioPharma Dive. The decision comes months after proponents had promised the decades-old medicine could help "hundreds of thousands of kids" with autism. This underscores the FDA's continued emphasis on precision in rare disease indications despite advocacy for broader use cases.
Novo Nordisk responds to FDA warning letter following 2025 PADE inspection
Novo Nordisk has issued a response to an FDA warning letter stemming from a 2025 Post-Approval and Drug Establishment (PADE) inspection, PharmExec reported. Specific details of the compliance issues were not disclosed. Worth watching because manufacturing quality concerns at a major insulin and GLP-1 manufacturer could have supply chain implications.
Lilly commits $3B to China manufacturing for oral GLP-1 capacity expansion
Eli Lilly is investing $3 billion over the next decade in China manufacturing operations to boost global supply of its oral GLP-1 candidate orforglipron, according to Fierce Pharma. The commitment includes both internal expansions and local CDMO partnerships. The substantial China bet reflects Lilly's confidence in next-generation obesity treatments and its strategic calculus around manufacturing footprint despite ongoing geopolitical tensions.
BioNTech co-founders step down to launch new mRNA venture amid rising losses
BioNTech's co-founders are stepping down from their leadership roles to establish a new mRNA-focused venture, Pharmaceutical Technology reported. The leadership transition comes as BioNTech posted a 57% increase in net losses for 2025, reflecting the post-pandemic normalization of COVID vaccine revenues. The move suggests confidence in mRNA's broader potential while signaling BioNTech's need for fresh strategic direction.
Veeva acquires Ostro for $100M to add AI chat tool for pharma brand engagement
Veeva Systems is acquiring Ostro for $100 million to gain its AI-powered chat tool designed for pharmaceutical brand engagement with consumers, per the report. The deal marks Veeva's expansion from its core B2B cloud software business into consumer-facing digital health tools. This signals the convergence of enterprise life sciences software with patient engagement platforms.
Lilly CEO Ricks pursues 'exit velocity' strategy to escape pharma's boom-bust cycle
Eli Lilly CEO David Ricks is working to achieve what he calls "exit velocity" to break free from the traditional boom-and-bust cycle that has historically plagued the pharmaceutical industry, Endpoints News reported. Ricks recently appeared on stage with Nvidia CEO Jensen Huang, highlighting cross-industry partnerships. The strategic vision reflects Lilly's efforts to sustain growth momentum from its obesity franchise while diversifying risk.
Red states bear brunt of reduced NIH funding cuts
Republican-leaning states are experiencing disproportionate impacts from recent reductions in NIH research funding, according to STAT. The funding cuts have implications for academic medical centers and biotech ecosystems in affected regions. This development may complicate political support for federal life sciences research appropriations going forward.
What to Watch
- Vertex's IgAN filing — The upcoming FDA submission for povetacicept will test regulatory appetite for novel complement inhibitors in kidney disease and could establish a significant new revenue stream beyond CF.
- Lilly's China bet — The $3B manufacturing commitment over ten years for oral GLP-1 production signals both confidence in orforglipron and calculated risk amid US-China tensions; any geopolitical escalation could complicate this strategy.
- Bimzelx market penetration — With multiple head-to-head wins now documented, UCB's ability to convert clinical superiority into market share gains against entrenched blockbusters will be the key commercial test.
- BioNTech's post-founder era — Leadership transition amid mounting losses raises questions about pipeline execution and whether the company can successfully pivot from COVID vaccines to oncology and other mRNA applications.
Market Snapshot
- GLP-1 manufacturing race intensifies: Lilly's $3B China investment underscores the strategic importance of oral formulation capacity as next-generation obesity drugs approach commercialization, with supply chain resilience becoming a competitive differentiator.
- Head-to-head data driving formulary wars: UCB's Bimzelx victories over Skyrizi and prior blockbusters demonstrate how comparative effectiveness trials are becoming essential ammunition for payer negotiations and market access in immunology.
- AI tools entering pharma marketing: Veeva's $100M Ostro acquisition reflects growing investor and strategic interest in AI-powered patient engagement platforms as pharma seeks direct-to-consumer digital channels beyond traditional advertising.